What antibody drug conjugate manufacturing has to control that an antibody process never did: why antibody drug conjugate linkers decide stability, release and the therapeutic window more than the payload does, what antibody drug conjugate analysis must report about drug to antibody ratio and its distribution rather than its average, where site specific conjugation buys homogeneity and what it costs in engineering, how handling a cytotoxic payload changes the facility and the people, and what a conjugation partner should demonstrate before a batch is booked

Specifying the programme

1. Choose the linker against the release mechanism you want. Cleavable linkers release payload under conditions found inside cells; non cleavable linkers release only on antibody degradation. Stability in circulation and release at the target are the two ends of the same trade, and the choice shapes everything downstream.
2. Specify the distribution, not just the average ratio. An average drug to antibody ratio can be produced by many different mixtures, and the unconjugated and heavily conjugated species behave differently in the body. The specification has to cover the distribution.
3. Decide stochastic against site specific conjugation early. Conventional conjugation is simple and produces a heterogeneous product. Site specific approaches produce a defined species and require antibody engineering and often a new process. Deciding late means redoing the antibody.
4. Set limits for free drug and related impurities. Unconjugated payload is a potent impurity with its own limit and its own assay. It must be controlled at release and monitored on stability.
5. Treat the payload as a containment problem. Highly potent compounds impose occupational exposure limits, containment engineering, cleaning verification and waste handling. Not every partner with biologics capacity can take this work.
6. Build the analytical package before the batch. Ratio and distribution, free drug, aggregation, identity, potency and stability indicating methods. These take longer to develop than the conjugation itself and are the usual critical path.

Heterogeneity is the characterisation problem

A conventionally conjugated product is a mixture of species differing in load and in site, and every analytical method sees that mixture differently. Characterising it properly means measuring the distribution, not summarising it.

That is why site specific approaches keep gaining ground: a defined species is easier to make consistently, easier to characterise and easier to defend, even though the route to it is longer.

The facility question comes first

Handling a highly potent payload requires containment, exposure monitoring and cleaning verification that most biologics facilities do not have. It narrows the list of possible partners considerably and it should narrow it at the start of the search.

Ask for the occupational exposure limit they work to and how they verify cleaning between products. A partner without a clear answer is not a candidate.

Common questions

Why is the linker more important than the payload?

Because payload potency is largely known while linker behaviour decides where that potency is delivered. Premature release produces systemic toxicity; excessive stability produces no effect at the target. The therapeutic window is largely a linker property.

What does drug to antibody ratio actually tell you?

An average. Two batches with the same average can contain very different proportions of unconjugated and heavily loaded species, which differ in clearance and toxicity. The distribution is the meaningful specification.

Is site specific conjugation worth it?

It gives a homogeneous product that is easier to characterise and often has a better profile, at the cost of antibody engineering and a more involved process. For programmes intending to go far, it is increasingly the default.

What should a conjugation partner demonstrate?

Containment appropriate to the payload with occupational monitoring, an established conjugation platform with distribution control, free drug and aggregation analytics in house, and cleaning verification between products.

Browse by service class

• Compare Gene synthesis on advertised prices